Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Presurgical pulmonary evaluation in renal transplant patients.

Sahni S, Molmenti E, Bhaskaran MC, Ali N, Basu A, Talwar A.

N Am J Med Sci. 2014 Dec;6(12):605-12. doi: 10.4103/1947-2714.147974. Review.

2.

Evaluation of neutrophil function during hemodialysis treatment in healthy dogs under anesthesia with sevoflurane.

Shimamura S, Kimura K, Katayama M, Mashita T, Maeda K, Kobayashi S, Sato R, Yasuda J.

J Vet Med Sci. 2014 Nov;76(11):1539-43. Epub 2014 Aug 21.

3.
4.

Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

DeAngelis RA, Reis ES, Ricklin D, Lambris JD.

Immunobiology. 2012 Nov;217(11):1097-105. doi: 10.1016/j.imbio.2012.07.012. Review.

5.

Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis.

Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I, Panagoutsos S, Passadakis P, Vargemezis V, Magotti P, Qu H, Mollnes TE, Ritis K, Lambris JD.

Blood. 2010 Jul 29;116(4):631-9. doi: 10.1182/blood-2010-01-264051. Epub 2010 Apr 27.

6.

Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Fung M, Lu M, Fure H, Sun W, Sun C, Shi NY, Dou Y, Su J, Swanson X, Mollnes TE.

Clin Exp Immunol. 2003 Aug;133(2):160-9.

7.
8.

Production of the third and fourth component of complement (C3, C4) by smooth muscle cells.

Ueda Y, Nagasawa K, Tsukamoto H, Horiuchi T, Nishizaka H, Ikeda K, Niho Y.

Immunology. 1996 Oct;89(2):183-8.

9.

Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor.

Guerrero R, Velasco F, Rodriguez M, Lopez A, Rojas R, Alvarez MA, Villalba R, Rubio V, Torres A, del Castillo D.

J Clin Invest. 1993 Jun;91(6):2754-60.

10.

Complement activation by cellulosic dialysis membranes.

Innes A, Farrell AM, Burden RP, Morgan AG, Powell RJ.

J Clin Pathol. 1994 Feb;47(2):155-8.

11.

Reactive oxygen product formation by human neutrophils as an early marker for biocompatibility of dialysis membranes.

Rosenkranz AR, Templ E, Traindl O, Heinzl H, Zlabinger GJ.

Clin Exp Immunol. 1994 Nov;98(2):300-5.

12.

Complement-induced granulocyte aggregation in vivo.

Hammerschmidt DE, Harris PD, Wayland JH, Craddock PR, Jacob HS.

Am J Pathol. 1981 Feb;102(2):146-50.

13.

Phorbol myristate acetate: in vivo effects upon neutrophils, platelets, and lung.

O'Flaherty JT, Cousart S, Lineberger AS, Bond E, Bass DA, DeChatelet LR, Leake ES, McCall CE.

Am J Pathol. 1980 Oct;101(1):79-92.

14.

Effect of intravenously injected killed pneumococci on leukocytes, complement, and phagocytosis in rabbits.

Reed WP, Jaffee P, Albright EL, Williams RC Jr.

Infect Immun. 1980 Sep;29(3):1021-7.

15.
16.
17.
19.

Alterations in activities of anaphylatoxin inactivator and chemotactic factor inactivator during hemodialysis.

McCormick JR, Kreutzer DL, Keating HJ, Hupp J, Despins A, Moore M.

Am J Pathol. 1982 Dec;109(3):283-7.

Supplemental Content

Support Center